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Cancers of unknown primary (CUPs), featuring metastatic dissemination in the absence of a
primary tumor, are a biological enigma and a fatal disease. We propose that CUPs are a
distinct, yet unrecognized, pathological entity originating from stem-like cells endowed with
peculiar and shared properties. These cells can be isolated in vitro (agnospheres) and pro-
pagated in vivo by serial transplantation, displaying high tumorigenicity. After subcutaneous
engraftment, agnospheres recapitulate the CUP phenotype, by spontaneously and quickly
disseminating, and forming widespread established metastases. Regardless of different
genetic backgrounds, agnospheres invariably display cell-autonomous proliferation and self-
renewal, mostly relying on unrestrained activation of the MAP kinase/MYC axis, which
confers sensitivity to MEK inhibitors in vitro and in vivo. Such sensitivity is associated with a
transcriptomic signature predicting that more than 70% of CUP patients could be eligible to
MEK inhibition. These data shed light on CUP biology and unveil an opportunity for ther-
apeutic intervention.
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Cancer of unknown primary (CUP) is the diagnosisreceived by patients that present multiple metastases in theabsence of a primary tumor anatomically or histologically
recognizable through a standardized work-up that includes
thorough body imaging and tissue immunohistochemistry1–4.
Although implying some uncertainties, the definition of CUP
applies to 1–2% of all malignancies and features a dismal median
survival (<1 year). The clinical course is, however, less aggressive
in a subset of cases (15–20%) displaying features reminiscent of
some specific tissue of origin, such as the neuroendocrine
carcinoma2,4.
So far, CUPs were investigated with two main pragmatic
clinical aims, such as to uncover the molecular or epigenetic
signature of a putative “tissue of origin”, and treat each CUP as a
high-grade metastatic tumor of that tissue or organ5–7, or to
identify mutated cancer genes and inform personalized targeted
therapies8,9. However, apart from a few exceptions, prediction of
a putative origin and application of tailored therapies negligibly
extended the overall survival of CUP patients, which remains
among the poorest in oncology3,4,10. To make progress, it seems
critical to adopt an alternative approach, and investigate CUPs as
a group of tumors sharing the common ability to disseminate in a
way that is (i) early and rapidly progressing; (ii) unrestrained by
those barriers in the tissue of origin that facilitate the growth of a
detectable primary mass; and (iii) associated with an early cell
differentiation block, which precludes formation of recognizable
tissues.
In this study, we isolated a panel of human CUP-initiating
stem-like cells, named “agnospheres”, able to reproduce a faithful
disease model that features early cell dissemination and formation
of established multi-organ metastases. We show that agnosphere
properties are cell autonomous and converge on constitutive
activation of the proliferative MAP kinase pathway, sustaining
expression, and activity of the MYC proto-oncogene. MEK
inhibition with trametinib causes agnosphere cell death, and
necrosis of experimental CUP tumors, without inducing negative
feedback mechanisms. Importantly, we also show that response to
trametinib is foreseen by an originally set up gene expression
signature, which, applied to patients’ tissues, predicts sensitivity
in a high percentage of CUPs, suggesting that common disease
molecular mechanisms are amply shared.
Results
Agnospheres display the genetic makeup of original tumors. In
a cohort of 61 early metastatic cancer patients (i.e., that presented
at first diagnostic imaging assessment without an evident primary
tumor), enrolled at our institution, 27 were diagnosed as CUPs
through a rigorous ad excludendum protocol that ruled out the
presence of a primary lesion or a defined tissue of origin2,4. In the
CUP cohort, fresh human specimens for biological studies could
be obtained only in eight cases (29%), including five biopsies and
three surgeries (Supplementary Tables 1 and 2). All eight samples
were transplanted in immunocompromised mice (patient-derived
xenografts, PDX), resulting in 6/8 engraftments (75% success
rate). Interestingly, CUP samples that did not engraft belonged to
a patients’ subset with prolonged survival: AGN47 (OS > 40 m)
and AGN913 (OS > 84 m). From PDX, or fresh human samples
whenever possible, we attempted spheroid cultures of stem-like
cells, named “agnospheres”, with a 75% of successful rate (Fig. 1a
and Supplementary Table 2). Briefly, five out of six patients that
provided agnospheres (AGN901, AGN906, AGN43, AGN67, and
AGN914) displayed the typical aggressive CUP presentation,
featuring (i) multiple metastases; (ii) the histological aspect of
poorly differentiated carcinomas lacking expression of markers
associated with specific organs or tissues, and (iii) rapidly lethal
clinical outcome (average overall survival: 11.5 months; Supple-
mentary Table 1). Agnospheres derived from the above patients
are hereafter indicated as AS901, AS906, AS43, AS67, and AS914,
respectively. Patient AGN47 presented with multiple metastases
but, unlike the above cases, displayed signs of differentiation,
leading to the diagnosis of “neuroendocrine CUP” and a better
prognosis. The corresponding agnosphere is henceforth indicated
as N-AS47.
We performed the genetic characterization of agnospheres and
the corresponding available human tissues (hereafter indicated as
“original tissues”), by whole-exome sequencing (Supplementary
Table 3): AS901 and AS67 resulted hypermutated, consistently
with the presence of a POLE mutation in AS901, and POLE and
POLQ mutations in AS67; AS906, AS43, and AS914 harbored
different combinations of cancer-associated genes. In contrast, N-
AS47 harbored no mutation in known oncogenes or tumor
suppressor genes (TSG; Supplementary Table 3). Copy-number
variation analysis of the two most commonly altered tumor
suppressor genes unveiled heterozygous loss of TP3 accompanied
by TP53 hemizygous mutation in AS43, and heterozygous PTEN
loss in both AS914 and N-AS47 (Fig. 1b and Supplementary
Table 3). The variant allele frequency is consistent with
heterozygosity (oncogenes) or hemizygosity (TSG) in agno-
spheres (Supplementary Table 3). This supports the pathogenic
meaning of the genetic alterations and suggests that agnospheres
are monoclonal cell populations, at least relatively to driving
genetic lesions. Interestingly, we recently showed that multiple
synchronous metastases, sampled at warm autopsy of patient
AGN43, are highly genetically related and, in particular, share all
the driver gene mutations11, thus indicating that agnospheres,
although derived from a single metastatic lesion, can be
representative of all patient’s metastases.
Conventional and spectral karyotypic analysis showed that
AS901, consistently with its hypermutated state, did not display
evident aberrations of chromosome number and structure
(Fig. 1c). In contrast, AS906, AS43, AS914, and AS67 (although
hypermutated), exhibited slightly increased ploidy and multiple
numerical and/or structural chromosome aberrations, while N-
AS47 showed multiple numerical but few structural aberrations
(Fig. 1c, d and Supplementary Notes). Although the sample size is
too small to generalize conclusions, the overall genetic analysis
indicated mutational and karyotypic heterogeneity among agno-
spheres, consistently with previous observations in 200 CUP
patients8.
Agnospheres are enriched in self-sustaining stem-like cells.
Agnospheres were isolated and propagated in suspension, in
highly stringent stem culture conditions12. Surprisingly, all
agnospheres were capable of self-renewing and long-term propa-
gating at clonal density in the complete absence of any exogenous
growth factor, including EGF or FGF, usually required for in vitro
isolation and long-term maintenance of the stem phenotype in
cancer stem cells from highly aggressive tumors12–15. Indeed, in
our previous studies, cancer stem cells derived from glioblastomas
or colorectal cancer metastases could be in vitro long-term pro-
pagated in the absence of exogenous growth factors only in rare
and highly aggressive cases, mostly featuring constitutive activa-
tion of the growth factor receptor/RAS pathway15–17. Among
these, for comparison with agnospheres, we choose, as repre-
sentative carcinoma-derived tumorspheres, colorectospheres
mCRC729 and mCRC0155, both generated from colorectal cancer
liver metastases, and harboring IGF-2 gene locus amplification or
KRAS mutation, respectively17. Moreover, we newly generated a
growth factor-independent melanosphere (mMS321), from a
visceral metastasis with unequivocal melanocytic differentiation in
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Fig. 1 Agnospheres can be isolated from cancers of unknown primary and display the genetic makeup of the original tumors. a Morphological
appearance of agnospheres derived from CUP tissues propagated in mice or directly from human tissues. b PTEN and TP53 copy-number variations
measured by qPCR in gDNA from agnospheres. Value= 1 indicates biallelic content; values < 0.7 (dotted line) indicate allelic loss, (n= 2 independent
experiments with similar results were obtained). c Representative G-banded karyotypes of agnospheres. A: marker chromosome. d Representative images
of spectral karyotypic analysis (M-FISH) on metaphases of: AS906 (n= 16) showing a near-diploid karyotype; AS43 (n= 9), containing two major clones
with different karyotypes (near-diploid and hypotriploid); AS67 (n= 20) with hypertriploid modal karyotype; AS914 (n= 20) showing a near-diploid modal
karyotype; and N-AS47 (n= 13), including three major clones (near-diploid, near-triploid, and near-tetraploid).
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the absence of a detectable primary skin lesion, and harboring a
BRAF mutation (Supplementary Table 1). Independently of exo-
genous growth factors, all agnospheres displayed the ability to self-
sustain the expression of high levels of transcription factors (TFs)
known to be major regulators of self-renewal and stem identity in
normal and neoplastic tissues, such as Polycomb repressors18 and
reprogramming TFs19,20. Specifically, Polycomb repressor EZH2
and BMI1 were highly expressed in the majority of agnosphere
cells (Fig. 2a–c and Supplementary Fig. 1a). Among reprogram-
ming TFs, prominent expression of MYC gene products, in the
absence of gene amplifications (Supplementary Fig. 1b), was
observed in all agnospheres (Fig. 2a–c). Co-expression of MYC
with OCT4, SOX2, and KLF4 was observed only in a fraction of
agnosphere cells, likely marking a subpopulation with enhanced
stem traits (Fig. 2b and Supplementary Fig. 1a). In tumorspheres,
Polycomb and reprogramming TFs were expressed as well,
although collectively at a lesser extent, in particular in colorecto-
spheres (Fig. 2c and Supplementary Fig. 1c). Interestingly, YAP/
TAZ, recently implied in reprogramming of differentiated cells
into stem cells21, was highly expressed in all aggressive CUPs, but
undetectable in N-AS47 (Fig. 2c).
As the activity of the above TFs is known to drive genetic
programs sustaining the embryonic stem (ES) status, in the
overall agnosphere transcriptome we investigated the expression
of an “ES cell signature”, based on transcription of 13 gene sets
collected in four main groups, including (i) the Polycomb and (ii)
the MYC target groups, (iii) a group encompassing targets of
NANOG, OCT4, and SOX2, and (iv) a group of genes specifically
expressed in cultured human ES cells (Fig. 2d and Supplementary
Data 1)22. By direct comparison, agnospheres and tumorspheres
displayed global levels of Polycomb and MYC target genes overall
similar and comparable to those of ES cells (Fig. 2d and
Supplementary Data 1), although N-AS47 and colorectospheres
displayed slighter repression of Polycomb targets. Notably, while,
in ES cells, maintenance of the transcriptional program sustaining
the ES status requires exogenous factors19,20, in agnospheres most
of the same program is driven in a fully cell-autonomous manner.
As the “ES cell signature” was previously shown to be enriched in
poorly differentiated aggressive human tumors, and directly
correlated with breast cancer tumor grade22 we investigated its
expression in our panel of CUP tissues (including four matched
with agnospheres: AGN901, 906, 43, and 47), and, for
comparison, in a previously reported panel of breast cancer
transcriptomes22. CUP tissues displayed an “ES cell signature”
globally weaker compared with agnospheres, as expected, but
significantly more enriched compared with grade 3 breast cancer
tissues (Fig. 2d and Supplementary Data 1), known to contain an
abundant fraction of cells with stem properties13. Overall
transcriptomic data suggest that CUP tissues contain a high
proportion of cells that retain stem traits, consistently with their
poorly differentiated histology.
Given the interconnection between stem phenotype, metastatic
ability, and epithelial–mesenchymal transition (EMT)23, we
assessed protein expression of EMT core TFs ZEB1 and SNAI2,
epithelial markers E-Cadherin and EpCAM, and mesenchymal
markers Vimentin and CD44 (Fig. 2c). Moreover, we analyzed
the full panel of core and accessory EMT TFs in the agnosphere
transcriptome (Supplementary Fig. 1d)24. Agnospheres derived
from CUP adenocarcinomas (AS901, AS43, and AS67, Supple-
mentary Table 1) and neuroendocrine carcinoma (N-AS47),
which maintained in culture an epithelioid phenotype (Fig. 1a),
did not display EMT TF or marker expression (Fig. 2c). In
contrast, AS906 and AS914, which derived from carcinomas with
sarcomatoid features (Supplementary Table 1) and formed loose
spheroids in culture (Fig. 1a), expressed ZEB1, SNAI2, CD44, and
Vimentin, but negligible levels of EpCAM and E-Cadherin
(CDH1; Fig. 2c and Supplementary Fig. 1e). Accordingly,
transcriptomic analysis showed global higher EMT TF expression
in AS906 and AS914, while the maximum levels were observed in
mMS321 (Supplementary Fig. 1e). This analysis showed also that
CUP tissues globally displayed higher EMT TF expression as
compared with agnospheres, possibly as result of contamination
by tumor microenvironment cells. Validation by tissue immu-
nostaining could not be performed for lack of material, leaving
undetermined the real EMT extent in original CUP tissues.
Altogether, these findings suggest that EMT seems constitutively
activated only in agnospheres derived from CUPs displaying
sarcomatoid (i.e., mesenchymal) features. In the other cases,
clearly EMT does not occur spontaneously in basic culture
conditions, but it could be activated by appropriate exogenous
signals and play a key role during metastatic dissemination.
Finally, in the agnosphere and CUP tissue transcriptome, we
also analyzed the expression of cell surface and functional stem
cell markers previously used for identification and/or prospective
isolation of cancer stem cells from different types of carcinoma.
In both agnospheres and CUP tissues, we found significant
expression of general markers, such as CD24, CD98, CD166,
ITGA6, and ITGB1, with the notable exception of CD133 that
was rarely expressed (Supplementary Fig. 1e)25. Interestingly, the
MYC target gene and “don’t eat me” immunosuppressive signal
CD47 (refs. 26,27) was broadly expressed (Supplementary Fig. 1e).
The overall heterogeneity of cell surface marker expression
prevented the design of a common strategy for future prospective
isolation of CUP cancer stem cells and further characterization of
agnosphere subpopulations.
Concerning functional properties, agnospheres kept in the
absence of exogenous growth factors displayed an in vitro
estimated fraction of clonogenic cells ranging between 15 and
44% in AS901, AS906, AS43, and AS67, which decreased to 4% in
AS914 and to a mere 0.09% in N-AS47 (Fig. 2e). The clonogenic
frequency inversely correlated with the population doubling time,
which was relatively short in the highly self-renewing agno-
spheres (2 days in AS901, AS906, and AS67, and 3.5 days in
AS43) and increased to ~5 and 10 days in AS914 and N-AS47,
respectively.
Overall these data indicate that agnospheres are enriched in
cells with transcriptional traits typical of ES cells, mirrored by
functional clonogenic properties, which are fully self-sustained in
the absence of exogenous growth factors. Such transcriptional
features are present also in CUP tissues, attesting to the faithful
phenotypic correspondence between the original tumors and the
agnospheres, and indicating that CUP tissues are highly enriched
in stem-like cells as well.
Agnospheres generate phenocopies of the original tumors and
contain a high percentage of tumor-initiating cells. Next, to
assess the agnosphere tumorigenic potential, we subcutaneously
transplanted 105 agnosphere cells in immunocompromised mice
(spheropatients). At the injection site (IS), tumors formed in all
mice, within 20 days in the case of all aggressive agnospheres, and
only after 3 months in the case of N-AS47, reflecting the slower
progression of the corresponding human tumor (Supplementary
Table 1) and the long in vitro cell population doubling time.
Importantly, agnospheres regenerated IS-tumors indistinguishable
from the original human tumors by histology and expression of
immunohistochemical markers (Fig. 3a and Supplementary
Fig. 2a), a defining prerogative of cancer stem cells28. Interestingly,
agnospheres retained in culture the same tissue marker expression,
thus behaving as tumoroids (Fig. 3a and Supplementary Fig. 2a)29.
This property highlights the agnosphere ability not only to pro-
liferate, but also to recapitulate pseudodifferentiative programs
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independently of microenvironmental cues. Consistently with the
phenotypic and transcriptional correspondence between agno-
spheres and original tumors (Fig. 2d), strong and widespread
protein expression of Polycomb repressors was displayed by both
original and IS-tumors (Fig. 3b and Supplementary Fig. 2b), as
well as by agnospheres (Fig. 2b), suggesting that agnosphere
culture conditions did not significantly modify genetic programs
and phenotypic traits inherited by original tissues.
In order to evaluate the tumor-initiating potential, we
challenged all agnospheres by stringent in vivo limiting dilution
serial transplantation experiments up to three passages. Remark-
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generate tumors after subcutaneous transplantation, determining
an estimated tumor-initiating cell (TIC) frequency ranging
between 0.3 and 25% at the first passage (P0), and increasing
up to 50% in AS901 and AS906 at the third passage (P2; Fig. 3c).
Not surprisingly, N-AS47 displayed a relatively low TIC
frequency (0,002%), consistently with its overall in vitro biological
properties and modest clinical aggressiveness (Fig. 3c). Notably,
TIC frequencies in aggressive agnospheres are comparable to the
TIC frequency (8.5%) that we measured in melanosphere
mMS321 after subcutaneous transplantation (Supplementary
Fig. 2c). Melanoma is known as the tumor displaying the highest
TIC frequency, also because the subcutis provides an orthotopic
environment favoring cell viability and spread30. In contrast,
tumorspheres derived from other aggressive cancers, when
assessed in the same in vivo conditions (subcutaneous transplan-
tation in NOD/SCID mice), display TIC frequencies 1–2 log lower
than agnospheres: colospheres up to 0.2% (ref. 31), breast cancer
mammospheres up to 0.1% (ref. 32), and glioblastoma neuro-
spheres up to 0.1% (ref. 33).
Altogether these findings highlight the agnosphere ability to
recapitulate the original CUP tumors, either by reproducing their
histological and pseudodifferentiative features, or by mirroring
their clinical aggressiveness in TIC content.
Agnospheres reproduce the multi-organ metastatic pattern of
CUP patients. We then assessed metastatic ability, by trans-
planting subcutaneously luciferase-labeled agnosphere cells from
four representative cases (AS901, AS906, AS43, and N-AS47).
After removing IS-tumors, to prevent both overgrowth and
interference with weaker luminescence from metastatic sites, we
longitudinally monitored spheropatients by in vivo imaging.
Increasing luminescent signals were detected in vivo at multiple
sites, and further visualized in the explanted organs (Fig. 4a–c).
Histopathological and immunohistochemical analysis showed
that agnospheres generate metastases phenocopying the original
and the IS-tumor (Fig. 4d and Supplementary Fig. 3a–c), indi-
cating that agnospheres retain specific pseudodifferentiative
programs rather independent from exogenous signals or tissue
contexts, and can adapt to grow in different environments. In
spheropatients transplanted with the aggressive agnospheres
(AS901, AS906, and AS43), the metastatic burden lead to the
clinical endpoint within 4 months, and the overall postmortem
analysis showed multiple metastatic sites in ~75% of mice
(Fig. 4e). In N-AS47 spheropatients, metastatic growth was not
fatal, mirroring the patient’s clinical course (characterized by a
long survival >40 months). However, at the experimental end-
point (7 months), widespread micrometastases and disseminated
single cancer cells were detected in 100% of mice, including a
remarkable fraction (54% of all mice), where the IS-tumor did not
grow (Fig. 4e).
Among the metastatic sites, we found axillary lymph nodes
(Fig. 4f), considered as loco-regional lymph nodes invaded by
lymphogenous spread, which often occurs in CUP patients as well
(Supplementary Table 1)4. The other organs colonized in
spheropatients were likely reached by hematogenous spreading,
with homing occurring not only in the primary capillary district
downstream venous dissemination (lung), but, often, downstream
systemic arterial circulation as well. The frequent colonization of
connective tissues, including peripancreatic fibroadipose tissue,
gonadal adipose tissue, kidney capsule, and the occasional
homing between myocardiocytes, suggested a predilection for
the connective/mesodermal soil, where micrometastases and
intravascular cancerous emboli could be often detected (Fig. 4d
and Supplementary Fig. 3a–c). This, again, is consistent with the
CUP metastatic pattern, which can include uncommon sites, such
as subcutaneous connective tissues and muscles, as observed in
several patients, including AGN906, AGN43, AGN914, AGN909,
AGN322, and AGN325 in our cohort (Supplementary Table 1).
Strikingly, in CUP spheropatients, metastatic cells efficiently
disseminated as early as within 10 days after injection, as
observed in organs explanted from 4/4 mice transplanted with
AS43. Dissemination occurred well before the IS-tumor became
palpable, suggesting that cells can initiate the process without
prior local expansion and, likely, without induction of a pre-
metastatic niche from an established tumor. Immunostaining of
explanted organs showed single disseminated tumor cells,
micrometastases and vascular emboli at multiple sites, mostly in
the lung and connective tissues around the organs, i.e., the same
sites where macrometastases develop (Fig. 4g). Interestingly,
single disseminated cells were identified by pan-cytokeratin
immunostaining, suggesting that, during metastatic spread, these
cells retain their epithelioid phenotype, or reside in a partial
EMT state.
Such a rapid and widespread, both lymphogenous and
hematogenous, metastatization is rather uncommon when TICs
or organoids from other aggressive carcinomas are transplanted
subcutaneously (i.e., ectopically), in contrast to neural crest-
derived melanoma cells, which, injected orthotopically under the
skin, can metastasize34. Consistently, we could not observe
metastatic dissemination by subcutaneously transplanting mice
with colosphere mCRC729, which, as mentioned above, derives
from a colorectal cancer metastasis and shares some properties
with agnospheres (Fig. 2a–d), in particular cell-autonomous
propagation. Indeed, after mCRC729 injection, IS-tumors formed
in 100% of cases, being in some cases locally invasive, but always
unable to form detectable metastases during 7-month in vivo
longitudinal monitoring and ex vivo organ imaging (Fig. 4e and
Supplementary Fig. 3d, e).
Overall, these findings attest that agnospheres, in particular
those from aggressive CUPs, retain a high spontaneous and
multi-organ metastatic ability, which recapitulates the CUP
Fig. 2 Agnospheres are enriched in stem-like cells that self-sustain their long-term propagation. a Heatmap showing gene expression levels of selected
transcription factors (TFs), quantified by qRT-PCR in agnospheres and tumorspheres derived from metastatic colorectal cancer (mCRC729) or melanoma
(mMS321). b Representative immunofluorescent stainings of stem cell markers in agnospheres. Arrowheads: marker co-expression; open arrows: cells with
single marker expression (n= 3 independent stainings of agnospheres with similar results were obtained). Scale bar, 50 μm. Inset: magnification of dotted
area. Scale bar, 10 μm. c Representative western blot analysis of Polycomb repressor factors, reprogramming and EMT TFs, and epithelial and
mesenchymal markers in agnospheres and tumorspheres mCRC729, mCRC0155, and mMS321 (n= 3 independent experiments with similar results were
obtained, molecular weights are expressed in kDa). d Heatmap showing the gene set enrichment analysis of the 13 gene sets included in the embryonic
stem cell signature22, performed on the transcriptome of human embryonic stem cell lines (hESC), agnospheres, tumorspheres from metastatic cancers,
CUP original tissues, and a panel of breast cancer tissues, pooled by grade (the average enrichment score is shown for each grade). Only significant
enrichment scores with a false discovery rate < 10% are shown (Supplementary Data 1). NOS: NANOG, OCT4, and SOX2. e In vitro limiting dilution
sphere-forming assay. For each agnosphere, plots generated by the ELDA software are shown, reporting the estimated stem cell frequency (percentage of
clonogenic cells) with confidence intervals (C.I.; AS901, AS43, AS67, and AS914: n= 3; AS906 and N-AS47: n= 4 independent experiments).
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Fig. 3 Agnospheres generate phenocopies of the original tumors and contain a high percentage of tumor-initiating cells. a Histopathological features
(hematoxylin and eosin staining, H&E) and immunohistochemistry with antibodies used for CUP diagnosis, in patient metastases (left columns), tumors
formed by agnospheres at the subcutaneous injection site (middle columns), and cultured agnospheres (right columns). Scale bar, 50 μm. A representative
experiment is shown (n= 3 independent stainings of agnospheres with similar results were obtained). b Immunofluorescent stainings of stem cell markers
in patient metastases (left columns) and tumors formed by the corresponding agnospheres at the subcutaneous injection site (right columns). Nuclei were
counterstained with DAPI. Scale bar, 50 μm. A representative experiment is shown (n= 3 independent stainings of agnospheres with similar results were
obtained). c In vivo limiting dilution assay. The indicated numbers of agnosphere cells (105–101) were transplanted subcutis into immunocompromised
mice (P0) and, where indicated, agnospheres were re-derived in culture and transplanted for a second (P1) or a third (P2) passage. TIC tumor-initiating cell
frequency, C.I. confidence interval.
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clinical presentation, and may represent a convenient tool to
explore every stage of the metastatic cascade.
Agnospheres are sensitive to MEK inhibition in vitro. As
described above, all agnospheres shared the distinctive ability to
proliferate and self-renew in the absence of any exogenous growth
factor. Moreover, agnospheres, including the slowly proliferating
N-AS47, were insensitive to an ample panel of exogenously
supplied growth factors, with the exception of AS67, which
showed a moderate proliferative response to EGF, NRG1, and
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could be associated with the presence of RAS oncogenic muta-
tions, known to confer growth independence to tumorspheres15,
only in the case of AS906 (HRAS-mutated) and AS914 (KRAS-
mutated; Supplementary Table 3). Remarkably, in all agno-
spheres, proliferative autonomy could be sustained by the
expression of several growth factors, among which EGF-like
ligands, neuregulins, HGF, and IGF-1/2 (Supplementary Fig. 4b),
accompanied by expression and phosphorylation of their
genetically unaltered cognate receptors (Fig. 5a), indicating the
occurrence of autocrine loops. Conversely, expression and
phosphorylation of the same receptors was almost undetectable in
tumorspheres that relied on cell-autonomous proliferative trig-
gers, such as BRAF (mMS321) or KRAS (mCRC0155) mutation,
or amplification of the IGF-2 genetic locus (mCRC729)17. These
findings prompted us to try to halt agnosphere proliferation by
blocking constitutively activated receptors, in particular those of
the EGFR family, which seemed prominently activated in all
aggressive agnospheres. Pan-EGFR family inhibition through
lapatinib or afatinib35 was assessed in three representative
agnospheres: AS901 (hypermutated), AS906 (HRAS mutant), and
AS43 (RAS pathway wild type; Supplementary Table 3). A sig-
nificant proliferative arrest, without cell death induction even
after a 14-day treatment, was observed only in AS43 (Supple-
mentary Fig. 4c, d). Indeed, although abolishing EGFR phos-
phorylation in all agnospheres, EGFR inhibitors partially affected
downstream signaling only in AS43 (Supplementary Fig. 4e).
Agnosphere partial or full resistance to EGFR inhibition could be
explained by the concomitant presence of the HRAS mutation (in
AS906), as described15, and/or other autocrine loops providing
bypass mechanisms that kept MAPK and AKT pathways con-
stitutively active (Fig. 5a and Supplementary Fig. 4e).
We therefore reasoned that the multiple mechanisms sustaining
agnosphere autonomous proliferation should converge onto the
MAPK pathway. As, indeed, agnospheres display high levels of
constitutively phosphorylated MEK1/2, in some cases comparable to
those of BRAF-mutated mMS321 (Fig. 5a), we challenged agno-
spheres with two selective, clinically approved, MEK1/2 inhibitors,
endowed with different mechanisms of action: (i) trametinib, known
to be the most potent MEK1/2 inhibitor, used in BRAF-mutated
melanomas36,37, or (ii) selumetinib, an earlier inhibitor, known to be
less effective than trametinib in fully preventing MEK1/2 activation
by BRAF. As assessed by dose–response experiments (Supplemen-
tary Fig. 4f), in three representative agnospheres trametinib strongly
affected cell viability at nanomolar concentrations, while selumetinib
was less effective even at maximal doses (Supplementary Fig. 4f), as
reflected by early signaling events, such as ERK1/2 and pRB
phosphorylation (Supplementary Fig. 4g). The biological effects
exerted in agnospheres by the two inhibitors were comparable to
those observed in BRAF-mutated mMS321 (Supplementary Fig. 4h).
Trametinib was therefore chosen for further experiments, showing
to be effective in 4/6 agnospheres, by inducing dramatic growth
arrest within 4 days in AS901 and AS906, and within 10 days in
AS43 and AS67 (Fig. 5b), and concomitant apoptosis, as indicated
by the appearance of the cell death effector cleaved-PARP protein
(Fig. 5c). In sensitive agnospheres (AS901, AS906, AS43, and AS67),
trametinib induced long-term inhibition of ERK1/2 phosphoryla-
tion, the direct MEK1/2 target, and downregulation of c-MYC,
known to be tightly regulated by proliferative signals via MAPK
pathway (Fig. 5c)38,39. c-MYC decrease (or disappearance, in the
most sensitive agnospheres) was accompanied by proportional
downregulation of its transcriptional target Cyclin D1, responsible
for G1–S cell cycle progression via CDK4/6-mediated pRB
hyperphosphorylation, which was consistently reduced as well
(Fig. 5c). Stabilization of the cell cycle inhibitor p27-KIP1, known
to be prevented by c-MYC, was also observed (Fig. 5c)39.
Interestingly, in sensitive agnospheres, trametinib did not cause a
rebound increased EGFR phosphorylation and expression, often
observed after MEK inhibition and resulting from relief of a negative
feedback from MAPK to receptors (Fig. 5c)37. Rather, in sensitive
agnospheres, EGFR phosphorylation and expression were decreased
(Fig. 5d). This suggests that agnospheres may lack this negative feed-
back from MAPK to receptors, resulting in an unrestrained
receptor–MAPK signaling axis, which could become addictive and
would eventually cause hypersensitivity to MEK1/2 inhibitors (see
“Discussion”). Conversely, trametinib was biologically ineffective in
N-AS47 (Fig. 5b), consistently with its inability to prevent ERK1/2
phosphorylation and downstream signaling (Fig. 5c), thereby
suggesting that N-AS47 can self-sustain proliferation through
pathways independent of MEK1/2, as recently shown in organoids
from neuroendocrine tumors40. Surprisingly, in KRAS-mutated
AS914, trametinib inhibited ERK1/2 phosphorylation but exerted a
late paradoxical effect, by increasing cell proliferation (Fig. 5b, c), as
described in several cell lines and tumors37. This effect was likely a
specific outcome of MEK1/2 inhibition, as it was observed after
selumetinib treatment as well (Supplementary Fig. 4i). The
mechanism of such paradoxical response does not involve EGFR
rebound upregulation; however, it likely contributes to keep cMYC
and Cyclin D1 highly expressed independently of ERK1/2 inhibition
(Fig. 5c).
Trametinib is effective in CUP preclinical models and its effi-
cacy is predicted in patients by a response signature. To eval-
uate the therapeutic efficacy of trametinib in preclinical models,
CUP tumors were generated by subcutaneous transplantation of
three representative agnospheres (AS901, AS906, and AS43).
After IS-tumor establishment, spheropatients were randomized
and treated with a dose of trametinib (1 mg/Kg/die) previously
shown to be well tolerated and effective in xenograft models
harboring BRAF mutation (Fig. 5c)37,41. We chose to primarily
monitor the therapeutic effect in the established IS (sub-
cutaneous) tumor, assuming that (i) the IS-tumor is not repre-
sentative of a conventional primary tumor, but rather of every
metastasis generated by the agnosphere in the mouse, given the
homogeneity of IS-tumors and metastases; (ii) the effect of
Fig. 4 Subcutaneously transplanted agnospheres reproduce the early and multi-organ metastatic pattern of CUP patients. a Outline of longitudinal
in vivo monitoring of spheropatients transplanted subcutis with luciferase-labeled agnospheres, followed by endpoint ex vivo organ imaging and histopathological
analysis. IS-tumor injection site tumor. b Representative in vivo images of mice transplanted with AS901, showing increasing bioluminescent signals at metastatic
sites at the indicated time points (d, days). Black tape was applied to mask the IS-tumor residual signal. c Representative macroscopic images of the most
frequent metastatic sites. Top: bioluminescent signals of different explanted organs; bottom: photographs of macrometastases. d Histopathology (H&E) and
immunohistochemistry for human CK18 or human Vimentin, revealing metastases in the indicated organs of mice transplanted with AS901 or AS906,
respectively. Scale bar, 50 μm. Representative experiments are shown (at least n= 3 stainings in independent organs were obtained with similar results). e Bar
graph showing the percentage of mice transplanted subcutis with agnospheres or colosphere mCRC729 that developed IS-tumors and/or metastases (AS901:
n= 33, AS906: n= 50; AS43: n= 44; N-AS47: n= 13; mCRC729: n= 14). f Bar graph showing the percentage of mice subcutaneously (s.c.) transplanted with
agnospheres as in e that displayed metastasis (mts) at each of the listed sites. g Immunostainings for pan-cytokeratin AE1/AE3 showing tumor cells disseminated
in organs explanted 10 days after AS43 subcutaneous injection. Scale bar, 50 μm (n= 4 independent experiments with similar results were obtained).
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trametinib is not expected on the early dissemination step of the
metastatic process, but on the growth of established metastases;
(iii) the IS-tumor can be more accurately and precociously
measured than metastases, which are multiple and delayed, and
evolve by an unpredictable pattern that prevents reliable long-
itudinal quantification. The inhibitory effect of trametinib on IS-
tumor growth was statistically significant throughout the
experiment (Fig. 5d). Accordingly, the time to reach the experi-
mental endpoint (tumor volume= 1600 mm3) was significantly
prolonged in all mice treated with trametinib as compared with
controls (Fig. 5e). Interestingly, histopathological analysis of
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compared with controls, contained an ample central necrotic area
surrounded by proliferating cells, still responding to trametinib
with ERK1/2 inhibition (Fig. 5f, g and Supplementary Fig. 4j).
This indicates that tumor volume measurement alone under-
estimates the trametinib biological effect, while in vitro pro-
liferation arrest and cell death reliably predict the in vivo tumor
tissue response to trametinib.
To attempt an evaluation of trametinib effects on spontaneous
metastases, we analyzed serial sections of whole lungs (the site
most frequently colonized in spheropatients), collected at the
experimental endpoint, and thus at a later timepoint in treated
mice. Nevertheless, we found that, in treated mice, the number
and size of metastatic vascular emboli were significantly reduced
as compared with controls (Supplementary Fig. 4k, l), indicating
that trametinib can also prevent the growth of disseminated cells.
To evaluate whether sensitivity to trametinib can be predicted in
CUP patients, we set up an original “trametinib response signature”.
To this aim, we correlated publically available data on the trametinib
response of 445 cancer cell lines (CCLs) with the respective gene
expression profiles42,43 (Supplementary Fig. 4m–o). The signature
ability to predict the trametinib response was first validated in an
independent dataset of 634 CCLs44 (Supplementary Fig. 4o), and
further confirmed in a panel including the six agnospheres and the
BRAF-mutated melanosphere mMS321. Here, the signature cor-
rectly predicted sensitivity in mMS321, AS901, AS906, AS43, and
AS67, and resistance in AS914 and N-AS47 (Fig. 5h), accordingly to
in vitro responses (Fig. 5b and Supplementary 4h). The signature
was then applied to the transcriptome obtained from paraffin-
embedded tissues of a retrospective cohort of patients, encompass-
ing (i) 15 CUPs, including those matched with four agnospheres
(Supplementary Tables 1 and 2); (ii) three metastatic BRAF-mutated
melanomas (including mMEL321 that originated mMS321), chosen
as positive controls for trametinib sensitivity; and (iii) ten metastases
from early metastatic, non-CUP patients (i.e., enrolled as potential
CUPs, but whose tissue of origin was then identified (Supplemen-
tary Table 1). The signature predicted trametinib sensitivity in all
BRAF-mutated melanomas, as expected, and in 11/15 CUPs (73%),
while it predicted sensitivity only in 3/10 early metastatic tumors of
known origin. Clear resistance was predicted in the neuroendocrine
CUP AGN47 (the origin of N-AS47), and in an early metastatic
merkeloma (mMERK44), another tumor of neuroectodermal origin.
All other cases (3/15 CUPs and 6/10 early metastatic tumors) were
below the significance threshold for being defined either as sensitive
or resistant (Fig. 5i). From these data, we can conclude that (i)
agnospheres and the corresponding original tumors were predicted
consistently, attesting that the signature retains its ability to reliably
classify suboptimal samples, such as paraffin-embedded tissues; (ii)
the majority of CUP tissues, but only a minor fraction of early
metastatic tumors of known origin, associated with trametinib
sensitivity independently of the presence of BRAF or RAS
mutations, thus suggesting that constitutive and addictive activation
of the MEK signaling pathway can be sustained by alternative
mechanisms, including growth factor receptor autocrine loops.
Finally, we also analyzed different synchronous metastases
collected at warm autopsy from patient AGN43 (the origin of
AS43)11, showing that all share the trametinib sensitivity
signature (Fig. 5j). This finding adds to the previously shown
genetic homogeneity of these metastases11 and suggests that, at
least in some cases, the cell-autonomous behavior of CUP stem-
like cells may translate in remarkable biological homogeneity and
drug sensitivity across metastatic sites, with favorable implica-
tions for CUP therapy.
Discussion
Isolation of stem-like cells from CUP patients provided, to our
knowledge, the first CUP experimental model, suitable to identify
genetic and molecular determinants that explain the disease
hypermetastatic phenotype, featuring early widespread dis-
semination, ability to quickly colonize multiple organs by adapting
to different microenvironments, and cell differentiation block.
Irrespective of their different genetic alterations, agnospheres
display common properties, among which the first and most
striking is proliferative and self-renewal autonomy: agnospheres
retain their ability to long-term propagate without differentiating
even in the absence of any exogenous growth factor, a property
seldom displayed by stem-like cells derived from other metstatic
tumors. We could associate this property with the cell-
autonomous expression of self-renewal and reprogramming
TFs, and the constitutive enrichment of a transcriptomic sig-
nature distinctive of ES cells22. In contrast, in ES cells, this genetic
program is driven by extracellular signals, whose withdrawal
causes ES differentiation20. Within this signature, genes con-
trolled by Polycomb repressors45 and by the MYC family46 were
strongly modulated, consistently with widespread expression of
their transcriptional drivers (BMI1 and EZH2, and MYC,
respectively). Interestingly, this ES signature was enriched not
Fig. 5 MEK inhibition is effective in vitro and in CUP preclinical models, and its efficacy is reliably predicted in patients by a gene expression
signature. a Representative western blot analysis of phosphorylated (p) and total proteins in agnospheres and tumorspheres (n= 3 independent
experiments). b Cell viability of agnospheres treated for 4 days (AS901 and AS906) or 10 days with 50 nM trametinib or vehicle (DMSO) normalized vs.
untreated cells (NT; AS901, AS43, and AS67 n= 4; AS906 and AS914 n= 3; and N-AS47 n= 5 independent experiments, mean ± SEM, ANOVA,
Bonferroni multicomparison test). c Representative western blot analysis of agnospheres treated 48 h (AS901, AS906, and AS67) or 96 h (AS43, AS914,
and N-AS47) with vehicle (−) or 50 nM trametinib (+) (p- phosphorylated, cl. PARP: cleaved PARP, MYC# c-MYC in AS901, AS906, AS43, AS67, and
AS914, and N-MYC in N-AS47; n= 3 independent experiments). d, e Mice were injected subcutis with agnospheres and, after tumor establishment,
randomized in two treatment groups (control and trametinib, 1 mg/Kg/die; AS901, n= 7 mice/group; AS906, control n= 6 mice and trametinib n= 7
mice; AS43, n= 6 mice/group). d Growth curves of tumor volume fold changes vs. day 0 (beginning of treatment; mean ± SEM, two-way ANOVA).
e Survival curve at the experimental endpoint (tumor volume= 1600mm3; Mantel–Cox test). f Representative H&E and immunohistochemical stainings
for Cyclin D1 and phospho-ERK1/2 of whole tumor sections derived from endpoint mice transplanted with AS906 and treated with control or trametinib
(n= 3 mice). Scale bar, 2 mm. Bottom row: magnification of pERK1/2 staining. Scale bar, 100 μm. g Quantification of necrotic, vital, and Cyclin D1-positive
areas in whole tumor sections from mice transplanted with AS906 (top) or AS901 (bottom), expressed as percentage of total tumor area (n= 3 mice/
group, mean ± SEM, two-way ANOVA, Sidak’s multicomparison test; ns not significant). h–j Bar graphs of enrichment scores of the trametinib response
signature in agnospheres and melanosphere mMS321 (n= 3 replicates) (h); tumor tissues from CUPs (AGN−), melanomas (MEL−), and early metastatic
cancers of known origin (H&N head and neck, BRE breast, MERK merkeloma) (i); and different metastases of CUP patient AGN43 (n= 3 fragments/
metastatic site, mean ± SEM) (j). Sensitivity to trametinib associates with a negative enrichment score of resistance genes (gene set enrichment analysis.
Only enrichment scores with a false discovery rate, FDR < 10% are considered statistically significant, p values and FDR values are reported in
Supplementary Data 1). The presence or absence (WT) of a mutated gene associated with trametinib sensitivity (BRAF, KRAS, HRAS, or NRAS) is reported.
Hypermut hypermutated, n/d not determined, ns not significant.
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only in agnospheres but also in original CUP tissues, indicating
that the entire tumor is mostly formed by cells with stem features,
and that, vice versa, agnospheres well represent the overall CUP
cell population, thus behaving like “tumoroids”29. This also
indicates that stem culture conditions used to select agnospheres
do not significantly modify the genetic programs expressed by the
original CUP cells.
The c-MYC proto-oncogene is well known for its role at the
crossroad between stem cell regulation and oncogenesis. Famous
for being included in the original Yamanaka cocktail that
reprograms differentiated fibroblasts to pluripotency47, c-MYC
has been recognized as a key factor to recruit quiescent stem cells
into proliferation, by providing not only direct stimulation of
the cell cycle, but also activation of metabolic genes that support
the bioenergetics needs of proliferating cells48. Overexpression of
the c-MYC proto-oncogene contributes to tumor onset and/or
progression, as indicated by findings in human tumors (that
overexpress MYC in ~30% of cases) and mouse models38,49.
Experimental c-MYC overexpression can confer addiction, so
that MYC knock-down causes regression of established tumors,
attesting its relevance for cell proliferation and survival50.
In agnospheres and original CUP tumors, high and constitutive
expression of MYC family genes (c-MYC and/or N-MYC) occurs
in the absence of MYC genetic alterations. c-MYC is expressed in
the agnospheres derived from the most aggressive cases, diag-
nosed as “poorly differentiated carcinomas of unknown origin”.
N-MYC alone is highly expressed in the neuroendocrine CUP,
consistently with its specific role in tissues of neuroectodermal
origin51.
A second feature shared by all agnospheres, which, again, can
be correlated with independency from exogenous signals, is the
ability to widely metastasize after subcutaneous transplantation:
indeed, agnospheres quickly disseminate, home, survive, and
thrive in multiple tissue contexts, where they consistently
reproduce the histology of the original tumors, including
expression of markers specific to each different patient, together
with lack of terminal differentiation. This adaptability is likely
conferred by the ability to sustain proliferative and pseudo-
differentiative programs in a niche-independent way. Impor-
tantly, our data indicate that such prerogative is passed on from
patients to the experimental CUP model through agnospheres,
likely as result of (epi)genetic mechanisms rendering the pro-
liferative pathway constitutive, either through growth factors
autocrine loops or altered signal transduction.
In spite of the above common traits, the agnosphere experi-
mental behavior diverged according to the different clinical
courses of the respective original patients: not surprisingly, the
frequency of TICs was unusually high and growth of established
metastases was rapid in agnospheres isolated from the most
aggressive cases, while the same features were decidedly blunted
in the N-AS47 from the long-survivor neuroendocrine CUP.
In looking for CUP liabilities, we reasoned that the variegated
panel of proliferative signals detected in agnospheres should
converge on constitutive activation of the MAPK pathway, known
to be a major inducer of MYC expression and activity38,39.
Interestingly, hyperactivation of the MAPK pathway has been
recognized as a distinctive feature of metastatic tumors in
general52 and CUP in particular53, together with MYC
overexpression54. We could demonstrate that 4/6 agnospheres
were addicted to the MAPK pathway and highly sensitive to the
specific MEK1/2 inhibitors trametinib or selumetinib37. Sensitivity
correlated with complete downregulation of c-MYC expression,
proliferation arrest and cell death in vitro, induction of massive
necrosis in experimental tumors growing at the agnosphere
injection site, and reduced growth at metastatic sites. Interestingly,
in many cancers displaying MAPK hyperactivation, including
those harboring RAS mutations, the administration of MEK1/2
inhibitors is poorly effective, as it interrupts negative feedbacks
reverberating from the MAPK pathway to tyrosine kinase recep-
tors. These feedbacks may include signals rapidly leading to
receptor downregulation, as well as long-term kinome transcrip-
tional reprogramming37. Evidence indicates that these mechan-
isms are likely and consistently disrupted in responsive
agnospheres, as trametinib did not induce a rebound effect of
tyrosine kinase receptor reactivation, but it rather induced
receptor downregulation. Conversely, in non-responsive agno-
spheres, MEK inhibitors either failed to block cell proliferation, or
paradoxically induced it. However, this is not surprising as, for
example, in normal ES cells, MEK inhibitors are used to promote
rather than to halt proliferation20. The mechanisms of resistance
to MEK inhibitors remains to be determined, but they likely
involve alternative signaling pathways that contribute to maintain
high levels of MYC gene expression. An attractive candidate is the
Wnt pathway, a main regulator of stem cell self-renewal, known to
upregulate MYC55.
To assess whether sensitivity to trametinib, a clinically
approved drug, could be predicted in CUP cases, and provide a
tool to stratify patients for trials, we elaborated an original “tra-
metinib response signature”. This signature correctly anticipated
the experimentally assessed response to trametinib in agno-
spheres, and was retrieved also in the matched patients’ tissues.
Thus validated, the signature predicted the response in a retro-
spective cohort of CUP cases. Despite the absence of BRAF or
RAS family mutations, usually associated with trametinib
sensitivity37, the majority of CUPs were classified as responders.
Interestingly, CUP sensitivity predicted by the trametinib sig-
nature approximates that of BRAF-mutated melanomas, while a
panel of aggressive metastases from carcinomas of known origin
did not display a responder signature. Overall, data presented in
this study indicate that constitutive activation of the MAPK
pathway, leading to MYC sustained expression, and the ensuing
stem and proliferative transcriptional programs, can be a CUP
prominent, widespread and distinctive pathogenetic mechanism
offering opportunities for therapeutic intervention.
Beyond CUP investigation, the integrated experimental
platform presented in this study can have far-reaching appli-
cations, as it is endowed by unique prerogatives, compared to
the metastatic models available so far34. First, while such
models are mostly based on genetically engineered mice, or the
use of conventional cells lines, either artificially manipulated to
become metastatic34, or injected in the hearth left ventricle to
get systemic multi-organ spread56, human agnospheres are
innately endowed with comprehensive metastatic programs,
faithfully inherited from the original tissue and passed on to the
mouse model. Moreover, with their properties, agnospheres can
help to overcome operational limitations recognized to current
metastatic models, such as being (i) slow and inefficient,
because generated late in progression by rare cell subpopula-
tions; and (ii) based on cooperation between cell-intrinsic and
environmental signals, that hamper successful colonization.
The model here described thus represents a next-generation
tool for functional validation of metastatic determinants, and
mechanistically supported therapeutic interventions in a broad
spectrum of aggressive tumors.
Methods
Human subjects. All patients were recruited at the Candiolo Cancer Institute,
FPO-IRCCS, according to ethical requirements and protocols approved by the
institutional Review Board on human experimentation. Informed consent was
obtained from all patients. All patient samples were de-identified before processing.
Suspected CUP patients were enrolled in an approved prospective observational
trial (Study Protocol N. 010-IRCC-10IIS-15, and following updates; last update:
v2.0-16.10.2018), where the diagnosis was attained through an “ad excludendum”
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diagnostic protocol in accordance with ESMO guidelines2. After diagnosis, patients
received the best standard of care, and provided archival and viable tissue speci-
mens, and blood samples.
Animal models. All animal procedures were performed according to ethical reg-
ulations and protocols approved by the Italian Ministry of Health. NOD.CB17‐
Prkdcscid/NcrCr mice (NOD/SCID), (RRID:IMSR_CRL:394, Charles River
Laboratories), 5- to 6‐week‐old male were used for all in vivo studies. Mice were
housed at a maximum of six per cage with a 14-h light/10-h dark cycle, in a
conventional animal facility with an ambient temperature and humidity of 20–26 °C
and 40%–60%, respectively, with food and water ad libitum. Mice were monitored at
a minimum of twice weekly for general performance status and euthanized when
volume of xenografts reached 1600mm3, or they displayed signs of distress, or
weight loss ≥ 20%.
Generation and culture of agnospheres and tumorspheres. Tumor tissue spe-
cimens derived either from CUP patients (AGN906 and AGN47), or PDX
(AGN901, AGN43, AGN67, and AGN914), or a melanoma patient (mMEL321)
were minced and digested with collagenase I (Gibco) at 2 mg/ml in culture medium
for 40 min at 37 °C. After filtration and red cell lysis, single-cell suspensions were
resuspended in culture medium, composed by: DMEM:F12 (Sigma),
N2 supplement (Life Technologies-GIBCO), BSA 0.5% (Sigma), heparin 4 μg/ml
(Sigma), 2 mM glutamine (Sigma), penicillin–streptomycin (EuroClone), and see-
ded in ultra-low-attachment flasks (Corning-Sigma). For AS914 and AS67, the
culture medium was supplemented with a chemically defined Lipid Concentrate
(Gibco). Culture medium was replaced the next day and used throughout propa-
gation. Spheroids (agnospheres) appeared in culture few days after seeding, and
stabilization occurred on average after 3–4 months. For dissociation, trypsin was
required for all agnospheres except for AS906 and AS914. mCRC729 and
mCRC0155, previously derived from colorectal cancer liver metastases17, were kept
in the same culture medium as above, supplemented with Lipid Concentrate
(Gibco). Agnospheres and tumorspheres will be available upon institutional
material transfer agreement approval.
Generation of patient-derived xenografts. Human CUP tumor specimens,
derived either from biopsy or surgery, were subcutaneously transplanted in
NOD/SCID mice (PDX). Tumors were explanted when reached a maximum
of 1600 mm3, and collected for further propagation and agnosphere derivation.
Histopathology. Immunohistochemical staining of formalin-fixed paraffin-
embedded (FFPE) tumor tissue sections derived from patients and animal models
was performed using Ventana Benchmark ultra System (Roche), or Bond Max
(Leica Biosystems) or Autostainer Link 48 (Agilent), according to the antibody
used (see reagents), and revealed with Liquid Diaminobenzidine (DAB)+ Sub-
strate Chromogen System (K3468, Dako), following standardized manufacturers’
instructions. For quantification of experimental tumor areas, stainings of repre-
sentative middle tumor sections collected at the experimental endpoint were
acquired with Nikon Eclipse Ti2 using the NIS Elements Imaging software. The
whole area was scanned at 4× magnification and analyzed with ImageJ (RRID:
SCR_003070). Percentage of hematoxylin-positive area or Cyclin D1-positive area
was normalized vs. total area for each sample. Necrotic areas were calculated as
total area minus vital area. Statistical significance was assessed by two-way
ANOVA (Sidak’s multicomparison test).
gDNA extraction and CNV analysis. Genomic DNA was isolated from agno-
spheres using Relia Prep TM gDNA Tissue Miniprep System (Promega), according
to manufacturer’s instructions. DNA was quantified using a Nanodrop
ND1000 spectrophotometer (Thermo Fisher Scientific). As normal control, gDNA
of PBMCs derived from a pool of five healthy individuals was used. PTEN, TP53,
c-MYC, and N-MYC copy-number variations were calculated after qPCR with the
2− ΔΔCt method using GREB1 as normalizer.
Mutational screening of FFPE tissue specimens. In tumor samples not analyzed
by WES, assessment of mutational status of KRAS, HRAS, NRAS, and BRAF
hotspot mutations was performed through OncoCarta™ Panel v1.0 (Agena
Bioscience) on gDNA extracted from FFPE tissues, according to manufacturer’s
instructions.
Chromosome G banding. Chromosome analysis by G banding was performed on
agnospheres. In order to increase the number of metaphases, cells were synchronized
with Synchroset (Euroclone S.p.A.) according to manufacturer’s instructions and
blocked with colcemid (10 μl/ml) for 1 h. Chromosome harvesting was carried out
according to standard procedures. Briefly, cells were incubated in 0.075M KCl
hypotonic solution at 37 °C for 10min, fixed in methanol–glacial acetic acid (3:1),
dropped onto glass slides and dried using specific conditions for optimal chromosome
spreading. G banding was performed by incubating slides in 2× SSC at 68 °C for
2min and eventually stained with Wright’s solution for 2min (ref. 57). Metaphase
images were captured using an Olympus BX61 microscope (Olympus Corporation)
and analyzed by CytoVision software (Leica Biosystems). An average banding reso-
lution of 300 bands was achieved. Aberrations were described according to the
International System for Human Cytogenetic Nomenclature, 2016 (ref. 58).
Chromosome M-FISH. Chromosome analysis by multicolor-fluorescence in situ
hybridization (M-FISH) was carried out on agnospheres by using a commercial
mixture containing 24 chromosome-specific painting probes labeled with different
fluorochromes (24×Cyte kit MetaSystems). Probes and metaphase chromosomes
denaturation and hybridization were performed according to manufacturer’s
instructions. Briefly, the slides were incubated at 70 °C in saline solution (2× SSC),
denatured in NaOH, dehydrated in an ethanol series, air-dried, then covered with
10 μl of the denaturated probe cocktail and hybridized for 24 h at 37 °C. Subse-
quently, the slides were washed with post-hybridization buffers and counterstained
with 10 μl of DAPI/antifade. The Metafer System and the Metasytems ISIS software
(Carl Zeiss) were used for signal detection and metaphase analysis. At least nine
metaphases along different culture passages exhibiting the same derivative chro-
mosomes were studied for each cell line.
RNA-seq and qRT-PCR. Growing agnospheres and tumorspheres were harvested
and RNA was extracted using RNeasy Micro Kit (Qiagen), following manufacturer’
instructions. For qRT-PCR mRNA was converted into first-strand cDNA using
superscript II Reverse Transcriptase (Invitrogen), according to manufacturer’s
instructions. Amplification was performed with ABI PRISM 7900 HT (Applied
Biosystem) using Taqman Probes (Applied Biosystem). Ct values were normalized
versus HPRT1 and represented in the heatmap as 40− Ct. Results are repre-
sentatives of at least two independent experiments.
For Quant-seq 3′ mRNA sequencing, total RNA from agnospheres and
tumorspheres or from FFPE patient tissues was purified using RNeasy Micro Kit
(Qiagen) or Maxwell® RSC RNA FFPE Kit (Promega), respectively. Total RNA was
quantified using the Qubit 2.0 fluorimetric Assay (Thermo Fisher Scientific).
Libraries were prepared from 100 ng of total RNA using the QuantSeq 3′ mRNA-
Seq Library Prep Kit FWD for Illumina (Lexogen GmbH). Quality of libraries was
assessed by using screen tape High-sensitivity DNA D1000 (Agilent Technologies).
Libraries were sequenced on a NovaSeq 6000 sequencing system using an S1, 100
cycles flow cell (Illumina Inc.).
Alignment and normalization of QuantSeq RNA data. Illumina novaSeq base
call (BCL) files were converted in fastq file through bcl2fastq (version v2.20.0.422,
Illumina Inc.). Sequence reads were trimmed using bbduk software (bbmap suite
37.31, Joint Genome Institute) to remove adapter sequences, poly-A tails, and low-
quality end bases (regions with average quality <6). Alignment was performed with
STAR 2.6.0a (RRID:SCR_015899)59 on hg38 reference assembly obtained from
cellRanger website (Single-Cell Gene Expression, 10× Genomics; Ensembl
Assembly 93). The expression levels of genes were determined with htseq-count
0.9.1 by using cellRanger pre-build genes annotations (Single-Cell Gene Expres-
sion, 10× Genomics; Ensembl Assembly 93). Genes with an average number of
CPM (counts per million) <5 and Perc of duplicated reads >20% were filtered out.
Data normalization were performed using edgeR (RRID:SCR_012802)60.
Analysis of embryonic stem cell signature. Transcriptional profiles of agno-
spheres and tumorspheres were first averaged across replicates, and then genes with
an average CPM < 1 across all samples removed. Then averaged transcriptional
profiles of spheres and transcriptional profiles of CUP tissues were converted in z-
score and the gene set enrichment analysis (GSEA)61 was performed using as input
the ES cell signature as described by Ben-Porath et al.22. The expression profiles
and clinical information of 942 breast cancer patients described by Ben-Porath
et al.22 were downloaded from barc.wi.mit.edu/benporath. Patients’ transcriptional
profiles were first converted in z-scores and GSEA performed as above. Then,
median enrichment score of each gene signature was plotted grouping patients
according to their breast tumor grade. Finally, gene expression profiles of human
ES cell lines H7, HUES1, HUES8, and HUES9 were retrieved from ref. 62 with
accession number GSE102311, and GSEA was performed after transcriptional
profiles were converted in z-scores. GSEA and associated statistics were computed
using the fgsea package in R statistical environment version 3.6.
Generation and validation of the trametinib response signature. The basal
expression profile of ~1000 CCLs was obtained using RNA-seq from Cancer Cell
Line Encyclopedia24,43 (https://portals.broadinstitute.org/ccle). Cell lines derived
from liquid tumors were discarded, and only cell lines derived from solid tumors
were used for the following analysis. The raw counts of each gene across the cancer
cell lines were normalized using edgeR63. Data on cell line response to trametinib
were previously generated by Rees et al.42 and expressed in terms of area under the
curve (AUC), which reflects the in vitro response to trametinib of each cancer cell
line24 over 72 h. In particular, lower values of AUC are associated with a higher
sensitivity to trametinib and vice versa. A total of 445 CCLs, for which both
trametinib response and expression data were available, were used to identify
marker genes associated to trametinib resistance, as described below. The gene
signature to predict trametinib response from transcriptional data was identified as
depicted in Supplementary Fig. 4m–o. First, we computed Pearson correlation
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coefficient (PCC) between the expression of each gene and trametinib potency
measured by mean of AUC across the 445 distinct CCLs selected, as described
above. We then considered the top 1000 genes with highest PCC as putative marker
genes of trametinib resistance, because higher expression of these genes is asso-
ciated with lower potency of trametinib across the panel of the 445 used CCLs.
Finally, a machine-learning approach based on recursive feature elimination (RFE)
and support vector machines (SVMs) was used to identify the 500 (out of 1000)
genes whose expression values were best at discriminating resistant from sensitive
trametinib CCLs64,65. In particular, we used linear SVMs that were trained and
tested using the kernlab package in the R statistical environment version 3.6
(ref. 66). For RFE, trametinib sensitive CCLs were defined as those which AUC
values were in the 5% quartile of trametinib AUC distribution across the 445 CCLs
used in this study. On the other hand, trametinib resistant CCLs were defined as
those whose AUC values were in the 95% quartile. We used GSEA to predict the
trametinib response by checking whether marker genes of trametinib resistance
identified as above were either downregulated or upregulated across a given
transcriptional profile (Supplementary Fig. 4m). Hence, in each transcriptional
profile, genes are first sorted form the most to the least expressed and then GSEA is
performed using as input the identified marker genes of trametinib resistance. A
positive enrichment score means that genes associated with trametinib resistance
are highly expressed in the transcriptional profile, thus predicting resistance of
these cells to trametinib treatment. Conversely, a negative enrichment score indi-
cates a low expression of marker genes of trametinib resistance, and thus it predicts
sensitivity to trametinib treatment (Supplementary Fig. 4n). Validation of the
method was performed by predicting the trametinib response in an independent
dataset of 634 CCLs from Garnett et al.44 (Genomics of Drug Sensitivity in Cancer:
https://www.cancerrxgene.org/), for which basal gene expression from microarray
and trametinib response in term of IC50 were available. We then computed the
percentage of correctly predicted sensitive and resistant CCLs (Supplementary
Fig. 4n). Specifically, CCLs sensitive to trametinib were defined as those with an
IC50 < 1 μM, while all the other were considered as resistant. We obtained an
average classification accuracy of ~76% across the two classes (sensitive and
resistant) of CCLs. In all the analyses described above GSEA and associated
statistics were computed using the fgsea package in R statistical environment
version 3.6.
Analysis of trametinib response signature. Agnospheres, tumorspheres, or
patient tissues transcriptional profiles were first averaged across replicates when
present, then genes with an average CPM < 1 across all samples filtered out. Before
applying GSEA, averaged transcriptional profiles of each sample was converted in
z-score. GSEA61 was performed using as input identified marker genes of trame-
tinib resistance with the fgsea package in R statistical environment version 3.6.
Immunofluorescence and cell immunohistochemistry. Samples undergoing
immunofluorescence were either FFPE tumor specimens or growing agnospheres
or colosphere mCRC729. The latter were harvested, fixed 10 min with PFA 4% at
4 °C, washed in PBS, suspended in bio-agar for cyto-inclusion (Bio-Optica) at
42 °C, and processed for inclusion in paraffin. All staining were performed as
previously described67. Images were acquired using a LEICA SPEII confocal
microscope, equipped with a 40× oil objective and a 1.5× zoom for a final mag-
nification of 600×. Optical single sections were acquired with a scanning mode
format of 1024 × 1024 pixels. Fluorochrome unmixing was performed by acquisi-
tion of automated-sequential collection of multichannel images, to reduce spectral
crosstalk between channels. For immunohistochemical staining, an additional
peroxidase blocking was performed in H2O2 3% methanol 50% incubated 20 min
in the dark. For primary and secondary antibody concentrations, see reagents.
Secondary antibodies were HRP-conjugated (Dako), and DAB substrate chromo-
gen kit (Dako) was used for detection. Nuclei were counterstained with hema-
toxylin. Images were acquired through LASV4.2 software and are representative
of at least three independent immunostainings.
Western blot analysis. Total protein were extracted using RIPA buffer supple-
mented with a protease inhibitor cocktail (Roche Life Science), NaVO3 1 mM, and
NaF 1mM, subjected to sonication, quantified using BCA methods (Pierce), and
20 μg were separated on SDS–polyacrylamide gradient gel 4–12% or 4–20%
(Invitrogen) and blotted onto nitrocellulose membrane. After blocking, primary
antibodies were incubated at the indicated concentrations (see reagents). After
incubation with HRP-conjugated secondary antibodies (Jackson Lab), enhanced
chemiluminescence (Biorad) was used for detection according to manufacturer’s
instructions and images were acquired with the ChemiDoc TouchTM Imaging
System (Biorad) through Image Lab software. β-Actin or β2-tubulin were used as
protein loading control as indicated. The results shown are representative of at least
three independent experiments.
In vitro limiting dilution assay. Agnospheres were dissociated and seeded at
limiting dilution concentration (1–100 cells/100 μl) in ultra-low-attachment 96-
well microtiters (Corning). “Positive tests” were defined as wells with primary
spheres with a diameter ≥ 100 μm. Stem cell frequency was calculated using the
ELDA software68 (http://bioinf.wehi.edu.au/software/elda/). Means and 95%
confidence intervals (CI) are shown (n ≥ 3 independent experiments). Primary
spheres were harvested, dissociated, and seeded at the same dilutions for a second
and a third passage to assess long-term propagation.
Cell viability. Agnospheres were dissociated and seeded in culture medium in 96-
microtiter wells at the concentration of 200 cells/100 μl in the case of AS901,
AS906, AS43, and AS67, 500 cells/100 μl in the case of AS914 or 1000 cells/100 μl
in the case of N-AS47. Trametinib (GSK1120212; Selleckchem) or vehicle (DMSO)
were added immediately after seeding and every 5 days at the indicated con-
centrations. ATP consumption was measured 4 or 10 days after cell seeding with
Cell Titer Glo (Promega) according to manufacturer’ instructions, using GloMax
96 Microplate Luminometer and GloMax®-96 software (Promega). In each
experiment, the average of relative luminesce values (n ≥ 6 technical replicates) was
normalized vs. untreated control and fold changes were reported (n ≥ 3 mean ±
SEM, ANOVA, Bonferroni multicomparison test).
In vivo agnosphere transplantation. To assess the tumorigenic potential, agno-
spheres were dissociated as single-cell suspensions and counted with trypan blue to
exclude dead cells. A total of 105 cells were resuspended in 50 μl of culture medium
mixed 1:1 with matrigel—growth factor reduced (BD Bioscience) and injected
subcutaneously in the flank of 5–6-week-old male NOD.CB17-Prkdcscid/J mice
(referred to as “spheropatients”), obtaining 100% engraftment efficiency. During
the procedure anesthesia with 2.5% isofluorane in 100% oxygen at a flow rate of 1 l/
min was delivered to mice. Tumors grown at the injection site (IS-tumors) were
explanted and FFPE to undergo histopathological evaluation and comparison with
original tumors, as detailed above for patients.
Tumor-initiating cell frequency (in vivo limiting dilution assay). For in vivo
LDA, single-cell suspensions of 105, 104, 103, 102, or 10 cells were subcutaneously
injected into immunocompromised mice (P0) as above. Tumor intake (formation
of IS-tumors) was monitored up to 7 months after transplantation or until spon-
taneous death, and the in vivo TIC frequency was calculated with the ELDA
software as above. Mice dead before the experimental endpoint that did not gen-
erate a tumor were excluded from the counts. From P0 tumors agnospheres were
re-derived in culture by enzymatic digestion with collagenase as above, and, after
1 week of recovery in culture, they were dissociated and transplanted for a second
passage in mice (P1) at the same cell dilutions as above69. In some experiments, the
procedure was further repeated for a third passage (P2).
Assessment of spontaneous metastases. Agnospheres and colosphere
mCRC729 were engineered to express luciferase. Briefly, single-cell suspensions
were seeded in ultra-low-attachment six-well microplates at 5 × 105 cells/well
concentration in 1.5 ml of culture medium. Lentiviral particles carrying pCMV-
Luciferase or pCMV-Luciferase-IRES-GFP transfer vectors were added at 5 MOI.
After 6 h, 1 ml medium was added, and 24 h later the medium was replaced.
Transduction efficiency was assessed at 72 h by fluorescence microscopy showing
98% in all agnospheres. Transduced agnospheres were dissociated to single-cell
suspensions, and 5 × 104 cells were injected as detailed above in the flank of NOD/
SCID mice. Within a month after transplantation, tumors reached ∼300 mm3 and
were surgically removed under anesthesia (as above) to prevent tumor overgrowth
during subsequent metastasis monitoring. Tumor volume was measured with a
caliper and calculated using the formula: (d)2 × (D)/2, where d and D are the minor
and the major tumor axis, respectively. Analgesics were delivered to the animals
according to institutional guidelines. Bioluminescence in vivo imaging was
acquired with IVIS® Lumina and IVIS imaging software (Caliper Life Sciences)
starting from the day after surgery. Luciferin (D-Luciferin potassium salt, Caliper
Life Sciences) dissolved in PBS (150 mg/kg) was administered to mice by sub-
cutaneous injection. Anesthesia was delivered in the induction chamber with 2.5%
isoflurane in 100% oxygen at a flow rate of 1 l/min and maintained during IVIS
imaging with a 1.5% isoflurane mixture as above at 0.5 l/min. To mask residual
signals from the subcutaneous tumor, a black tape was applied during imaging.
Luminescent signals were monitored weekly until mice reached the clinical end-
point. For ex vivo imaging, luciferin was administered as above, mice were
euthanized by carbon dioxide inhalation and all organs were immediately
explanted and analyzed with IVIS. Organs were FFPE to undergo histopathological
evaluation and comparison with original tumors as above. The frequency of
metastatic sites was assessed by ex vivo organ luminescence and by immunohis-
tochemistry of CUP-specific markers in organ sections. Such frequency could be
underestimated for missed identification of micrometastases in some organs. To
assess early dissemination, mice transplanted with AS43 were euthanized 10 days
after subcutaneous injection, and explanted organs were FFPE and analyzed
as above.
In vivo trametinib treatment. Unlabeled agnospheres were inoculated subcutis in
immunocompromised mice. When tumors reached ~150 mm3, mice were rando-
mized in two groups (control and trametinib-treated) using LAS software70. For
treatment, trametinib was dissolved in hydroxi-methylcellulose 0.5%-Tween 80 and
administered by oral gavage at 1 mg/Kg/die (therapeutic range in preclinical
models: 0.3–3 mg/kg/die)41. Tumor volume was measured and calculated as above,
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and expressed as fold changes vs. day 0 for each mouse. For each experiment, n ≥ 6
mice/group were used. Statistical significance was determined by two-way
ANOVA. The survival curve was generated considering a tumor volume of 1600
mm3 as experimental endpoint, and statistical significance was calculated using
log-rank (Mantel–Cox test).
Statistical analysis. Results were expressed as mean ± standard error of the mean
(SEM) of at least three independent experiments. Statistical comparisons were
performed using Prism v8.0 software (RRID:SCR_005375; GraphPad). Chi-squared
test was used for limiting dilution experiments performed by ELDA software.
ANOVA (Bonferroni’s multiple comparison test correction) was used for assess-
ment of in vitro trametinib and selumetinib effect. Two-way ANOVA was used for
tumor growth curves, Mantel–Cox test for survival curves and two-way ANOVA
(Sidak’s for multiple comparisons) for evaluation of vital/necrotic tumor areas. A p
value <0.05 or a false discovery rate < 10% was considered significant. For RNA-seq
analysis the fgsea package in R statistical environment version 3.6 was used.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
Complete datasets related to WES analysis of somatic mutations, referring to
Supplementary Table 3, were deposited in the European Genome-phenome Archive
(EGA), under the accession code EGAS00001004868. Raw data relative to 3′UTR-Seq,
referring to Figs. 2d and 5g–I and Supplementary Fig. 1d, e were uploaded in the Gene
Expression Omnibus (GEO) repository, under the accession code GSE167473. Datasets
from public databases are available at these web links: Cancer Cell Line Encyclopedia:
https://portals.broadinstitute.org/ccle; Genomics of Drug Sensitivity in Cancer: https://
www.cancerrxgene.org/. Source data are provided with this paper.
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